Selvigaltin (GB1211), an orally accessible small molecule galectin-3 inhibitor developed being a treatment for liver fibrosis and cirrhosis, was evaluated to assess the influence of hepatic impairment on its pharmacokinetics and safety to address regulatory prerequisites. Members have been also excluded if they had clinically substantial abnormalities in electrocardiogram (ECG) https://stephenfopps.get-blogging.com/39743204/top-selvigaltin-galectin-3-inhibitor-secrets